Nicholas Galakatos, PhD, has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 21 years of industry and investment experience in the healthcare sector, including being a General Partner in a healthcare venture capital firm since 2000. From 1997 to 2000, Dr. Galakatos was Vice President of New Business at Millennium Pharmaceuticals (NASDAQ: MLNM) and a member of the Management Team. During that time he co-founded Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was Chairman. Prior to Millennium he was an Associate at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Novartis (formerly Ciba).
Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School.
Dr. Galakatos represents Clarus on the Board of Directors of Aerovance, Link Medicine, Nanostring, and Taligen. In addition, he is the Lead Director at Affymax (NASDAQ:AFFY) and is a Director of Aveo, and Portola.
Previous directorships include Caliper (NASDAQ: CALP), Critical Therapeutics (NASDAQ: CRTX), Millennium Predictive Medicine (acquired by Millennium), Syrrx (acquired by Takeda), TransForm (acquired by J&J) and Hypnion (acquired by Eli Lilly).
